Form 4 for DNLI Denali Therapeutics Inc.

Accepted 2022-06-27 00:00:00 ET · period of report 2022-06-23 · accession 0001628280-22-018113 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2022-06-27	2022-06-23+	DNLI	Tessier-Lavigne Marc	Dir	D - Sale to Iss	$30.72	-60.0K	1.98M	-3%	-$1.84M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-06-23	D	D	13,250	$31.10	2,017,106	D	—	—	(F1) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F2) Includes 5,986 unvested restricted stock units.
2	Common	Common Stock	2022-06-24	D	D	6,766	$31.08	1,970,356	D	—	—	(F4) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.00 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F2) Includes 5,986 unvested restricted stock units.
3	Common	Common Stock	2022-06-24	D	D	39,984	$30.53	1,977,122	D	—	—	(F3) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F2) Includes 5,986 unvested restricted stock units.